|
| Press Releases |
|
 |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub 
Mar 6, 2026 15:05 HKT/SGT
|
|
|
Hong Kong Tech Innovators Drive Success at Mobile World Congress and 4YFN Barcelona 2026
Mar 6, 2026 13:08 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 6, 2026 12:12 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Mar 6, 2026 10:00 HKT/SGT
|
|
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 16:00 HKT/SGT
|
|
|
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 5, 2026 16:47 JST
|
|
|
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 5, 2026 16:38 JST
|
|
|
Galaxy Corporation Leads "K-Entertech" IPO Rush as Nasdaq Vice Chairman's Surprise Visit Boosts Listing Prospects
Mar 5, 2026 15:30 HKT/SGT
|
|
|
Core Concepts Physiotherapy Partners with Podiatry Quest to Deliver Enhanced Assessments for Patients with Plantar Fasciitis
Mar 5, 2026 12:30 HKT/SGT
|
|
|
FinHarbor Completes Core Deployment of Hybrid Neobank Platform for Asterium in Uzbekistan
Mar 5, 2026 08:20 HKT/SGT
|
|
|
Formerra Appoints Tom Kelly as Chief Executive Officer
Mar 4, 2026 21:00 HKT/SGT
|
|
|
Philippine Hotel Innovation Summit 2026 Concludes in Manila, Setting a New Blueprint for the Future of Hospitality
Mar 4, 2026 20:07 HKT/SGT
|
|
|
Hong Kong International Jewellery Show opens today showcasing global designs and trends
Mar 4, 2026 19:51 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
